Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

JDP Therapeutics Announces Positive Results from Pivotal Phase 3 Trial of QZYTIR(TM) for Acute Urticaria. Study Achieves Primary Endpoint and Key Secondary Endpoints
  • USA - English


News provided by

JDP THERAPEUTICS INC

Jun 25, 2018, 06:00 ET

Share this article

Share toX

Share this article

Share toX


BLUE BELL, Pa. (PRWEB) June 25, 2018 -- JDP Therapeutics Inc., a privately held specialty pharmaceutical company focused on developing and commercializing proprietary product candidates for use in the hospital and urgent care settings, announced today that its pivotal Phase 3 clinical trial, ETTAU-03, evaluating QZYTIR(TM) (IV cetirizine) to treat acute urticaria, met primary and key secondary endpoints.

QZYTIR(TM) gives patients the ability to recover from acute symptoms while not causing a whole new set of problems. This is long overdue

Post this

Following approval by U.S. Food and Drug Administration (FDA), QZYTIR(TM) may be the only product indicated for acute urticaria, which is the most common symptom of acute allergic reactions. Cetirizine oral tablet has been marketed by Pfizer as Zyrtec® for allergic rhinitis and chronic urticaria since 1995, and later by McNeil as an OTC product since 2008.

The ETTAU-03 study is a randomized, double-blind, active controlled study evaluating the efficacy and safety of QZYTIR(TM) (IV cetirizine) for the treatment of acute urticaria. The trial enrolled a total of 262 patients from 22 treatment centers across U.S. and Canada who had a diagnosis of acute urticaria and needed treatment with antihistamine injections to alleviate their acute allergic reaction symptoms. The patients were treated with either QZYTIR(TM) 10 mg/mL or the active control diphenhydramine injection 50 mg/mL, which is the current standard of care.

The primary endpoint of ETTAU-03 established statistical non-inferiority of QZYTIR(TM) compared to diphenhydramine injection in reducing a key symptom pruritus score two hours after treatment. Key secondary endpoints, including reduced 2nd visit return rate to treatment center and time spent in treatment center, demonstrated QZYTIR(TM)’s statistical superiority to the comparator, diphenhydramine injection. Other secondary endpoints, such as less adverse events, less sedation, reduced rescue drug usage, and reduced symptom recurrence, further indicated statistical superiority of QZYTIR(TM) compared to diphenhydramine injection. Detailed trial results will be submitted for presentation at a future scientific conference or for publication in a journal.

"JDP’s pivotal Phase 3 trial of QZYTIR(TM) in acute urticaria signals the completion of development for this exciting product and advancement to the regulatory NDA stage for marketing registration in the United States, Canada, and other countries," said Jie Du, Ph.D., president of the company. Dr. Du added, "There is a significant unmet need among patients with acute urticaria requiring treatment with antihistamine injections. Treatment options are very limited with no innovation in the last ~65 years. The only available antihistamine injection is the 1st generation H1 antagonist diphenhydramine injection involving a significant amount of unwanted and well-known side effects. JDP’s clinical program (ETTAU-02 and ETTAU-03) validated the capacity of QZYTIR(TM) (IV cetirizine) to fulfill this important unmet need."

Dr. Bill Berger (Former President, American College of Allergy, Asthma and Immunology) further added, “It should not be that in life-threatening situations, we are still using older medications – there is a gaping need. Diphenhydramine injection also causes anticholinergic effects; if you drive with diphenhydramine injection after discharge, that can be a DUI charge due to sedation; it affects your judgement. QZYTIR(TM) gives patients the ability to recover from acute symptoms while not causing a whole new set of problems. This is long overdue.”

JDP anticipates filing an NDA with FDA for marketing approval of QZYTIR(TM) for acute urticaria in adults and children in Q3 2018. Similar filings and regulatory registrations will be pursued for Canada, Europe and rest of the world.

About QZYTIR(TM) (IV cetirizine)
QZYTIR(TM) is a proprietary injectable product of cetirizine (IV cetirizine) being developed for the treatment of acute urticaria, the most common symptom of acute allergic reactions, for the hospital, urgent care, and clinic markets. Due to the acute nature of this disease, an injectable product is needed to provide an immediate onset of action. When approved, it may be the only product to be indicated for acute urticaria.

A market QUANT study surveyed 110 physicians and revealed that 86% of responding doctors had indicated readiness to use QZYTIR(TM) (IV cetirizine) in place of the current therapy, diphenhydramine injection. Physicians cited QZYTIR(TM)’s lack of side effects as compared to those associated with diphenhydramine as the most compelling reason underlying their support for the QZYTIR(TM) treatment.

Two additional independent market research studies with in-depth clinician interviews confirmed the findings that QZYTIR(TM) will be able to fulfill the unmet need of the current therapy.

Acute urticaria is the most common symptom of acute allergic reaction, a serious and potentially life-threatening condition which has been growing at concerning rates with very limited options for treatment. QZYTIR(TM) (IV cetirizine) will offer a superior treatment to the current therapy for the first time in the last ~65 years.

About JDP Therapeutics Inc.
JDP Therapeutics Inc., a privately held specialty pharmaceutical company, is focused on developing and commercializing proprietary product candidates principally for use in the hospital and urgent care settings. Its lead product candidate QZYTIR(TM) has successfully completed the pivotal Phase 3 clinical trial for the treatment of acute urticaria, the most common symptom of acute allergic reactions, for use in hospitals and clinics.

JDP Therapeutics focuses on developing small molecule therapeutics to treat life threatening diseases with significant unmet medical needs, primarily for use in the hospital and clinical setting. The company develops unique dosage forms, novel formulations, and new indications for proven chemical entities to achieve their full therapeutic and market potential. This approach mitigates risk, shortens the development cycle, leads to a well-defined regulatory pathway, and fully characterizes clinical needs for each product opportunity.

For further information about JDP, please email: info(at)jdptherapeutics(dot)com

Safe Harbor Statement Regarding Forward-looking Statements
The statements in this release and oral statements made by representatives of JDP relating to matters that are not historical fact, including without limitation those regarding the timing or potential outcomes of research or clinical trials, any market that might develop for any of JDP’s product candidates are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of JDP and/or its partners to develop, manufacture and commercialize, JDP’s ability to fund such efforts with or without partners, and other risks.

Jonathan Black, JDP THERAPEUTICS INC, +1 (215) 661-8557, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.